Business Wire

“Dense Air” The Neutral Host Small Cell Operator

Del

Today we introduce “Dense Air”, a new wholesale network operator, that “enhances and extends” the coverage and capacity of existing Mobile Networks as a “Carrier of Carriers” operator, typically on a neutral host basis. The announcement coincides with the 2018 Mobile World Congress in Barcelona, Spain, where Dense Air is exhibiting (26 February–1 March 2018).

Dense Air uses Airspan’s comprehensive portfolio set of 4G and 5G small cells to offer services to Mobile Operators in licensed spectrum dedicated to small cells for densification/extension deployments.

“We are very excited about the opportunity to deliver a completely new type of service to mobile carriers. Dense Air’s wholesale service offering will complement the investments carriers have made in their Macro RAN,” said Paul Senior, Acting CEO of Dense Air. “By adding small cells, running in dedicated licensed spectrum to Macro networks at cell edge either outdoors or indoors, we can dramatically improve the service experience to end users, increase speeds and network capacity. Importantly, Dense Air does not and will not offer retail mobile services and does not compete in any way with mobile service providers.”

“The economics of both 4G and 5G small cell deployments can be dramatically improved when deployed using a neutral host solution, i.e. when a single network of small cells can host multiple operators. Our mission is to help MNOs and MVNOs improve their networks by densification without the need to spend CAPEX”.

Dense Air is an optimised network densification and network extension service.

  • Solution delivered using Indoor and Outdoor Small Cells
  • Service operates in licensed, dedicated spectrum
  • Dense Air small cells provide services on a “Neutral Host” basis
  • We support 4G LTE and LTE Pro networks and later 5G NR
  • Dense Air fills coverage holes and capacity weak spots in Macro Networks
  • Services are offered on a wholesale “Carrier of Carriers” basis to Mobile Network Operators
  • We DO NOT compete with Mobile Operators or other Service Providers
  • Our services are delivered in Urban, Suburban or Rural areas
  • The focus is on mobile use cases, including eMBB, IoT, Public Safety
  • We also enable Private LTE Networks for Large Enterprises and Governments

Airspan’s product and technologies for 4G LTE and 5G are naturally suited to small cell centric network architectures. Airspan's unique innovation and technology leadership in intelligent small cells with integrated LTE relay and millimeter-wave backhaul technologies will allow Dense Air to massively densify traditional mobile networks.

About DENSE AIR:

Dense Air is based in London, UK and has offices in Ireland and Belgium, it’s target launch markets. Dense Air uses unique “carrier of carriers” neutral host small cell technologies to deliver cost effective densification to any existing LTE Mobile Carrier or Service Provider. Dense Air is conducting extensive trials and Proof-of-Concepts in 2018 and will offer commercial services in 2019.

www.denseair.net

media@denseair.net

About Airspan Networks Inc.:

Airspan (OTC PINK : AIRO) is a leading 4G and 5G RAN solution provider, with over 1000 customers in over 100 countries. Airspan is regularly recognized as a leader and pioneer in LTE Access and innovative Backhaul solutions. Airspan has an expansive product portfolio, which includes indoor and outdoor small cells, and all-outdoor, compact Micro and Macro base stations, a variety of user devices and network optimization products. These connectivity solutions operate in bands from 400 MHz up to 6.4 GHz and 60-80GHz millimeter wave. www.airspan.com.

Airspan is not subject to the informational reporting requirements of the Securities Exchange Act of 1934 and, accordingly, does not file reports, financial statements, proxy statements, information statements or other information with the Securities and Exchange Commission. This press release may contain forward-looking statements. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. We do not assume any obligation to update any forward-looking statements.

Airspan Networks Inc.

mediarelations@airspan.com

Contact information

Dense Air
Paul Senior
Tel: 01895 467100
media@denseair.net

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Octapharma announces approval of new Nuwiq® product strengths in Europe, increasing dosing flexibility for patients with haemophilia A18.6.2018 07:06Pressemelding

Octapharma announced today that the European Medicines Agency (EMA) has approved an extension of marketing authorisation for its human cell line-derived recombinant factor VIII (rFVIII) product, Nuwiq®. New single dose vial strengths of 2500, 3000 and 4000 International Units (IU) will be available in Europe, in addition to the current strengths of 250, 500, 1000 and 2000 IU. The new Nuwiq® vial strengths have been available in the US since September last year, following approval by the FDA. Nuwiq® is indicated in adults and children of all ages for on-demand treatment and prophylaxis, including during surgery, to prevent and control bleeding episodes in patients with haemophilia A. This expanded array of vial strengths has the potential to increase treatment options for patients with haemophilia A by improving dosing flexibility. Patients who previously required more than one vial per infusion may be able to reduce the number of vials needed. Nuwiq® is the only rFVIII available in an

STATS and SpokeHub Partner to Power Deeper, More Meaningful Conversations Around the 2018 FIFA World Cup18.6.2018 07:00Pressemelding

Today, STATS, the worldwide leader in sports data and intelligence, and SpokeHub announced a new partnership to bring STATS Insights to SpokeHub’s social engagement platform, connecting worldwide World Cup football (soccer) fans with content that is more impactful. Download the app today to see the match scores, player insights, and engage with World Cup fans everywhere! STATS Insights leverages more than 37 years of research experience to deliver deep historical and comparative statistical insights, play-by-play descriptions and in-game trends based on events as they happen in the match. Before, during and after each match, SpokeHub will harness STATS Insights to amplify conversations among World Cup football communities. During the game, live Insights will deliver trends on players and teams based on in-game events, statistics and milestones. “No sporting event gets global attention like the World Cup, and every fan is looking for deeper analysis around their favorite teams and playe

Celltrion Completes Resubmission to FDA for Proposed Trastuzumab Biosimilar18.6.2018 02:53Pressemelding

Celltrion (KRX:068270) has made a resubmission to the FDA (U.S. Food and Drug Administration) to obtain its marketing approval for CT-P6, a proposed mAb biosimilar to Herceptin® (trastuzumab). Celltrion submitted its abbreviated Biologics License Applications (aBLAs) for CT-P10 and CT-P6 to the FDA in April and May of last year, respectively. However, it received CRLs (complete response letters) from the FDA related to the warning letter issued by the FDA in January 2018, related to the manufacturing facility in Incheon, South Korea. Celltrion had completed the resubmission for the approval of CT-P10, a proposed biosimilar to Rituxan® (rituximab) last month. In accordance with FDA regulations, the approval procedure will be usually finalized within six months from the resubmission, so Celltrion expects the approval for the U.S. market of the two proposed biosimilars within this calendar year. FDA has notified Celltrion of its re-inspection schedule regarding regular audit results, and

CES Asia: Innovation at the Speed of 5G15.6.2018 14:59Pressemelding

CES Asia® 2018 wrapped today with the rapid pace of global innovation front and center over the show’s three day duration. The next stage of technology advancements were showcased across vehicle tech, robotics, artificial intelligence (AI), virtual and augmented reality, digital health and more. The event, 24 percent larger than last year in terms of footprint, cemented itself as the place to fully experience how the pace of technology is accelerating globally. CES Asia, the premier event for tech innovation in the Asian marketplace, will return to Shanghai, China, June 11-13, 2019. “5G and AI are igniting growth across the entire tech ecosystem changing the way we interact with technology and the world around us,” said Gary Shapiro, president and CEO, Consumer Technology Association (CTA)™. “It’s incredible to see technology refining and reinventing itself at such a fast pace. Just six months ago we were at CES with life-altering tech all around us. This week, I saw that technology re

bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin™ Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia at Annual Congress of the European Hematology Association15.6.2018 10:00Pressemelding

bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from the completed Phase 1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase 3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy in patients with TDT and non-β0/β0 genotypes, will be presented in an oral session on June 16 at the 23rd Annual Congress of the European Hematology Association by Franco Locatelli, M.D., Ph.D., of the IRCCS Ospedale Pediatrico Bambino Gesù of Rome, Italy. “The maturing data from HGB-204 and HGB-207 suggest that one-time treatment with LentiGlobin may address the underlying genetic cause of TDT. With our refined manufacturing process, the majority of patients with TDT and non-β0/β0 genotypes are transfusion-free and producing total hemoglobin at normal or near-normal levels,” said David Davidson, M.D., chief medical officer, bluebird bio. “We are on track to submit a m

bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association15.6.2018 10:00Pressemelding

bluebird bio, Inc. (Nasdaq: BLUE) today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease (SCD) will be presented in an oral presentation on Saturday, June 16 at the 23rd Congress of the European Hematology Association (EHA) by Julie Kanter, M.D., Medical University of South Carolina, Charleston, South Carolina. “The consistent production of increased amounts of anti-sickling HbAT87Q in the Group C patients reflects the substantial positive impact of the changes introduced with the amended HGB-206 study protocol and refined manufacturing process. All four Group C patients with greater than or equal to three months follow-up are making over 30 percent anti-sickling HbAT87Q. The first patient treated, now with six months of follow-up, is producing over 60 percent anti-sickling HbAT87Q with a normal total hemoglobin level of 14.2 g/dL,” said David Davidson, M.D., ch